We are live on
!
Find out more
Pictet Asset Management Portfolio holdings
AUM
$105B
1-Year Est. Return
38.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+38.07%
3 Year Est. Return
+113.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$90B
AUM Growth
-$2.64B
(-2.9%)
Cap. Flow
+$2.07B
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
17.41%
Holding
2,101
New
60
Increased
1,058
Reduced
623
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$327M |
| 2 |
Broadcom
AVGO
|
+$315M |
| 3 |
Mastercard
MA
|
+$262M |
| 4 |
Intuit
INTU
|
+$226M |
| 5 |
Digital Realty Trust
DLR
|
+$149M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$169M |
| 3 |
WCN
Waste Connections
WCN
|
+$141M |
| 4 |
NextEra Energy
NEE
|
+$134M |
| 5 |
Cadence Design Systems
CDNS
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.36% |
| 2 | Industrials | 16.63% |
| 3 | Healthcare | 13.3% |
| 4 | Financials | 8.12% |
| 5 | Consumer Discretionary | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Quest Diagnostics
DGX
$26.1B
| $44.3M | 0.05% |
261,583
-39,646
| -13% | -$6.51M |
|
327
CSX Corp
CSX
$92.4B
| $44.2M | 0.05% |
1,501,397
+371,689
| +33% | +$11.8M |
|
328
Vital Farms
VITL
$489M
| $44.2M | 0.05% |
1,449,589
+544,235
| +60% | +$19.6M |
|
329
Colgate-Palmolive
CL
$73.7B
| $43.7M | 0.05% |
466,786
+10,285
| +2% | +$921K |
|
330
Allstate
ALL
$66.6B
| $43.6M | 0.05% |
210,764
-10,365
| -5% | -$2.02M |
|
331
Duke Energy
DUK
$96.2B
| $43.6M | 0.05% |
357,518
-6,762
| -2% | -$771K |
|
|
MRUS
332
DELISTED
Merus
MRUS
| $43.4M | 0.05% |
1,032,101
+274
| +0% | +$11.9K |
|
333
Paychex
PAYX
$42.4B
| $43.3M | 0.05% |
280,497
+38,733
| +16% | +$5.7M |
|
334
Paylocity
PCTY
$7.5B
| $43.2M | 0.05% |
230,651
-219,593
| -49% | -$43.9M |
|
335
Atlassian
TEAM
$38.6B
| $43.2M | 0.05% |
203,566
+114,193
| +128% | +$30.1M |
|
336
Neurocrine Biosciences
NBIX
$16.1B
| $43.1M | 0.05% |
387,574
-223,545
| -37% | -$28.3M |
|
337
PNC Financial Services
PNC
$101B
| $42.9M | 0.05% |
244,306
+3,772
| +2% | +$712K |
|
338
Scotiabank
BNS
$109B
| $42.7M | 0.05% |
901,692
+217,124
| +32% | +$10.9M |
|
339
Louisiana-Pacific
LPX
$5.15B
| $42.7M | 0.05% |
464,685
-76,859
| -14% | -$8.02M |
|
340
Brown & Brown
BRO
$23.5B
| $42.7M | 0.05% |
343,108
+19,226
| +6% | +$2.15M |
|
341
Vaxcyte
PCVX
$8.97B
| $42.2M | 0.05% |
1,050,678
+32,833
| +3% | +$2.63M |
|
|
BNY
342
Bank of New York Mellon
BNY
$110B
| $41.6M | 0.05% |
495,869
+10,523
| +2% | +$884K |
|
343
Enbridge
ENB
$113B
| $41.5M | 0.05% |
937,063
-30,670
| -3% | -$1.33M |
|
344
Nu Holdings
NU
$65.2B
| $41.3M | 0.05% |
4,031,564
+240,146
| +6% | +$2.84M |
|
345
Capital One
COF
$134B
| $41.2M | 0.05% |
229,682
+1,739
| +0.8% | +$328K |
|
346
Aon
AON
$74.9B
| $41M | 0.05% |
102,615
-39,567
| -28% | -$15.2M |
|
347
W.W. Grainger
GWW
$61.6B
| $40.7M | 0.05% |
41,206
-2,816
| -6% | -$2.91M |
|
348
GE Vernova
GEV
$277B
| $40.4M | 0.04% |
132,231
-12,112
| -8% | -$4.22M |
|
|
EA
349
DELISTED
Electronic Arts
EA
| $40.3M | 0.04% |
278,672
-108,994
| -28% | -$14.7M |
|
350
Doximity
DOCS
$4.5B
| $40.1M | 0.04% |
691,411
+584,684
| +548% | +$36.9M |
|
Similar funds
Pictet Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Pictet Asset Management held 2,101 positions worth $90B, down 2.9% from $92.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Pictet Asset Management's Q1 2025 filing shows 60 new, 1,058 increased, 623 reduced and 92 closed positions. Its largest new stake was Verona Pharma: 703,063 shares worth $44.6M. The largest sale was Intra-Cellular Therapies Inc., an estimated $187M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Industrials and Healthcare.
- Pictet Asset Management's largest Q1 2025 buy was Verona Pharma: 703,063 shares worth $44.6M.
- Pictet Asset Management added most to Synopsys in Q1 2025, an estimated $327M increase.
- Pictet Asset Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $187M.
- Pictet Asset Management fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q1 2025, selling an estimated $46.5M.
- Pictet Asset Management's ten largest holdings make up 17% of its $90B portfolio in Q1 2025.
- Pictet Asset Management opened 60 new positions and closed 92 in Q1 2025.
- Pictet Asset Management's portfolio value fell 2.9% quarter-over-quarter to $90B.
Based on Pictet Asset Management's 13F filing for Q1 2025, filed 5 May 2025.